5-Year quest to halt liver damage in hepatitis b patients
NCT ID NCT07412236
Summary
This large, 5-year study aims to see if adding the drug Hydronidone to standard antiviral therapy can prevent serious liver complications in people with chronic hepatitis B who already have liver scarring (fibrosis). It will involve about 1,200 adults and compare Hydronidone against a placebo to measure if it reduces the risk of liver failure, cancer, or death.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact
Conditions
Explore the condition pages connected to this study.